Clinical Trials Search | Clareo Health

Showing 1-2 of 2 trials

MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing

NCT05794880

This is a single arm pilot study for patients with hematologic malignancies receiving unrelated or haploidentical related mobilized peripheral stem cells (PSCs) using the CliniMACS system for alpha/beta T cell depletion plus CD19+ B cell depletion with individualized ALC-based dosing of ATG to study impact on engraftment, GVHD, and disease free survival

LeukemiaAcute Myeloid Leukemia in RemissionMyelodysplasia+10 more

Medical College of Wisconsin40 participantsStarted May 2023

Milwaukee, Wisconsin, United States

RECRUITINGPHASE2/PHASE3

Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis

NCT06756152

GVHD prevention using a combination of post-transplantation cyclophosphamide in combination with abatacept, vedolizumab and Ruxolitinib in children and young adults with hematoloblastosis after myeloablative conditioning regimen with treosulfan/TBI, etoposide, fludarabine after HSCT from matched unrelated and haploidentical donors

Biphenotypic Acute LeukemiaAcute Lymphoblastic LeukemiaMyeloblastic Leukemia+3 more

Federal Research Institute of Pediatric Hematology, Oncology and Immunology50 participantsStarted Jul 2024

Moscow, Russia

Data from ClinicalTrials.govTerms

Filters

Filters

MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing

Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis

MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing

Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis